A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

NCT00528333 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Lintuzumab (SGN-33)
DRUG: Low dose cytarabine
DRUG: Placebo

Sponsor

Seagen Inc.